No Antidotes For Eliquis, Savaysa, And Xarelto To Stop Acute Bleeding
When we read this September 25, 2015 Medscape article, “EMA Recommends Approval of Idarucizumab (Praxbind), a Dabigatran-Specific Antidote”, we recalled this alarming fact: At the present time there is...
View ArticleXarelto / Savaysa / Pradaxa / Eliquis: Effect Of Platelet Inhibitors
Some newer oral anticoagulants have been associated with bleeding-related adverse reactions including gastrointestinal and intracranial bleeds. And that problem is the primary complaint that the...
View ArticleEliquis Might Be Safer Than Xarelto, But Neither Has Approved Antidote
In a November 9, 2015 news report, “Antithrombotics Have Varied Risk of Causing Major Bleeds”, there is a summary of one presentation the American Heart Association 2015 Scientific Sessions:...
View ArticleEliquis, Savaysa, And Xarelto Worry Doctors Because No Antidote, Still
A few recent articles address the fact there is no way to quickly restore normal clotting for patients in need of emergency surgery or to stop a major bleeding episode while on Eliquis, Savaysa, and...
View ArticlePossible Blood Level Testing For Eliquis / Xarelto / Pradaxa / Savaysa
As background, Xarelto (rivaroxaban) belongs to a class of medicines known as the direct oral anticoagulants (DOAC), which also includes Pradaxa (dabigatran), Eliquis (apixaban), and Savaysa...
View ArticleNo Clinical Trials Comparing The Safety Of Eliquis To Xarelto Done Yet
In two medical study reports it seemed that Xarelto (rivaroxaban) was more likely to be involved in a serious bleeding event as an adverse reaction than was either Pradaxa (dabigatran) or Eliquis...
View ArticleEarlier Pradaxa Settlements Do Not Stop Filing Of New Pradaxa Lawsuits
As can be seen from the following set of drug safety alerts, Pradaxa has caused significant concern among doctors and patients since soon after it first became available for use in the US. In early...
View ArticlePradaxa And Xarelto May Double The Risk Of Heart Attacks Some Patients
In March 2017 the British Journal of Clinical Pharmacology published this article, “Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct...
View ArticlePradaxa vs. Warfarin: Rehospitalizations For Serious Bleeding Events
Thomas J. Moore, of the Institute for Safe Medication Practices, recently wrote a “Perspective” piece about new Pradaxa-versus-warfarin study, which is described below. Medical researchers reviewed...
View ArticlePradaxa Liver Injury: Label Changes Warning About This Increased Risk
We are watching to see whether the FDA and/or European drug regulators require a Pradaxa liver injury label change adding a new warning about an increased risk of acute liver failure and drug-induced...
View Article
